Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease1
- 1 May 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 73 (10) , 1603-1610
- https://doi.org/10.1097/00007890-200205270-00014
Abstract
Background. Posttransplant lymphoproliferative disease (PTLD) is closely linked to primary Epstein-Barr virus (EBV) infection and a defect of EBV specific cellular immunity is supposed to be the basis of PTLD. However, EBV load is so far the only marker proposed to evaluate PTLD risk, and no study has investigated the role of specific anti-EBV T lymphocytes (EBV-TL). Methods. We therefore prospectively measured the EBV-TL by enzyme-linked immunospot (elispot) assay, in correlation to EBV load by real-time quantitative PCR and lymphoproliferation occurrence in 45 liver transplanted children. Results. EBV load at the time of primary infection was high in all patients irrespective to subsequent emergence of PTLD. Seven patients developed PTLD, all of them following primary EBV infection. All seven had low EBV-TL (25,000 copies/μg DNA). Both parameters can be combined in a 100% positive predictive index. Healing from lymphoma was characterized by rapid EBV-TL increase concomitant to decreasing viral load. EBV-TL follow-up helped to adapt immunomodulation. No patient had PTLD whenever EBV-TL were above 2/mm3. Conclusions. We conclude that high viral load is systematic in patients who underwent primary EBV infection and is indicative of the PTLD risk only if there is low concomitant cellular immune response. Healing from PTLD requires modulation of immunosuppression, and appearance of EBV-TL.Keywords
This publication has 24 references indexed in Scilit:
- Characteristics of Epstein-Barr virus primary infection in pediatric liver transplant recipientsJournal of Hepatology, 2000
- EPSTEIN-BARR VIRUS-INDUCED POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERSTransplantation, 1999
- Pediatric liver transplantation with cadaveric or living related donors: Comparative results in 90 elective recipients of primary graftsThe Journal of Pediatrics, 1999
- SERIAL MEASUREMENT OF EPSTEIN-BARR VIRAL LOAD IN PERIPHERAL BLOOD IN PEDIATRIC LIVER TRANSPLANT RECIPIENTS DURING TREATMENT FOR POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE1Transplantation, 1998
- MANAGEMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE IN PEDIATRIC LIVER TRANSPLANT RECIPIENTS RECEIVING PRIMARY TACROLIMUS (FK506) THERAPYTransplantation, 1998
- Early Signs And Risk Factors For The Increased Incidence Of Epstein-Barr Virus-Related Posttransplant Lymphoproliferative Diseases In Pediatric Liver Transplant Recipients Treated With TacrolimusTransplantation, 1997
- HUMAN CYTOTOXIC T LYMPHOCYTE RESPONSES TO EPSTEIN-BARR VIRUS INFECTIONAnnual Review of Immunology, 1997
- Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative diseaseBlood, 1994
- EPSTEIN-BARR VIRUS SEROLOGY AND EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS IN PEDIATRIC LIVER TRANSPLANT RECIPIENTSTransplantation, 1993
- REVERSIBILITY OF LYMPHOMAS AND LYMPHOPROLIFERATIVE LESIONS DEVELOPING UNDER CYCLOSPORIN-STEROID THERAPYThe Lancet, 1984